This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n21http://linked.opendata.cz/resource/drugbank/drug/DB05013/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/drug/DB05013/identifier/national-drug-code-directory/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n8http://www.drugs.com/ppa/
n10http://www.rxlist.com/
n24http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB05013/identifier/chemspider/
n14http://linked.opendata.cz/resource/drugbank/drug/DB05013/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/patent/
n18http://linked.opendata.cz/resource/drugbank/drug/DB05013/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB05013/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/resource/drugbank/drug/DB05013/identifier/pubchem-substance/
n22http://linked.opendata.cz/resource/drugbank/drug/DB05013/identifier/kegg-drug/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB05013
rdf:type
n3:Drug
n3:description
Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis. Before approval, ingenol mebutate was called PEP005 as an investigational drug. PEP005 is a selective small molecule activator of protein kinase C (PKC) extracted from the plant Euphorbia peplus, whose sap has been used as a traditional medicine for the treatment of skin conditions including warts and cancer. PEP005 also has potent anti-leukemic effects, inducing apoptosis in myeloid leukemia cell lines and primary AML cells at nanomolar concentrations.
n3:dosage
n9:271B6256-363D-11E5-9242-09173F13E4C5 n9:271B6257-363D-11E5-9242-09173F13E4C5 n9:271B6258-363D-11E5-9242-09173F13E4C5 n9:271B6259-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
There is no half-life quantity since ingenol mebutate is a topical treatment.
n3:indication
For the topical treatment of actinic keratosis.
owl:sameAs
n24:DB05013
dcterms:title
Ingenol Mebutate
adms:identifier
n14:66913 n15:5293863 n17:12015710 n18:Ingenol_mebutate n19:50222-503-47 n20:6918670 n21:DB05013 n22:D09393
n3:mechanismOfAction
The exact mechanism of action of ingenol mebutate in actinic keratosis is unknown. It is presumed to involve primary necrosis then neutrophil-mediated inflammation and antibody-dependent cell death of residual disease cells. Additionally in early studies, PEP005 was shown to be an effective activator of PKC-delta and PKC-delta translocation into nucleus and membranes. PEP005 also downregulates the expression and activity of PKC-alpha. PEP005 induced modulation of PKCs leads to Ras/Raf/MAPK and p38 activation and AKT/PKB inhibition.
n3:patent
n12:2301082%20
n3:routeOfElimination
There is no route of elimination since ingenol mebutate is a topical treatment.
n3:synonym
Picato PEP005 ingenol mebutate Ingenol 3-angelate 3-Ingenyl Angelate
n3:toxicity
The most common adverse reactions are local skin reactions at the application site, headache, periorbital edema,and nasopharyngitis.
n3:volumeOfDistribution
There is no volume of distribution quantity since ingenol mebutate is a topical treatment.
n5:hasAHFSCode
n6:84-92%20
n3:foodInteraction
No food effects found.
n3:proteinBinding
There is no plasma protein binding quantity since ingenol mebutate is a topical treatment
n3:synthesisReference
Ogbourne SM, Suhrbier A, Jones B, Cozzi SJ, Boyle GM, Morris M, McAlpine D, Johns J, Scott TM, Sutherland KP, Gardner JM, Le TT, Lenarczyk A, Aylward JH, Parsons PG: Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004 Apr 15;64(8):2833-9.
foaf:page
n8:ingenol-mebutate.html n10:picato-drug.htm
n3:IUPAC-Name
n4:271B625E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6264-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6263-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6260-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6261-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6262-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B625C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B625A-363D-11E5-9242-09173F13E4C5 n4:271B625D-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B625B-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n16:D06BX02
n3:H-Bond-Acceptor-Count
n4:271B6269-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B626A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6265-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6266-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6267-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6268-363D-11E5-9242-09173F13E4C5
n3:absorption
Since ingenol mebutate is a topical treatment, the systemic absorption is less than 0.1 ng/mL.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
75567-37-2
n3:category
n3:clearance
There is no clearance quantity since ingenol mebutate is a topical treatment.
n3:Bioavailability
n4:271B626F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6271-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6272-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B626E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B626D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6270-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B625F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B626B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B626C-363D-11E5-9242-09173F13E4C5